Horizon Pharma Ord (HZNP) 17.84 $HZNP Generic D
Post# of 273258
Posted On: 09/02/2016 11:07:31 PM
Horizon Pharma Ord (HZNP) 17.84 $HZNP
Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn
PR Newswire - Fri Sep 02, 6:40AM CDT
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, Stock-Callers.com presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX). Download the free research reports on these stocks today: http://stock-callers.com/registration
AGN: 235.96 (-1.80), AKRX: 26.47 (-0.21), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer
PR Newswire - Thu Sep 01, 3:30PM CDT
Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer. Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller. She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration Degree from the Ivey Business School, University of Western Ontario. Ms. Burkett replaces Stephen Lemieux who has resigned to pursue other opportunities.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals(TM) Inc. Appoints New Chief Financial Officer
CNW Group - Thu Sep 01, 3:30PM CDT
Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer. Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller. She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration Degree from the Ivey Business School, University of Western Ontario. Ms. Burkett replaces Stephen Lemieux who has resigned to pursue other opportunities.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Horizon (HZNP) Rayos Receives USPTO Notice of Allowance
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:22AM CDT
Horizon Pharma (HZNP) announced that it has received a notice of allowance from the U.S. Patent and Trademark Office with claims covering Rayos.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), HZNP: 17.84 (-0.78), CORT: 5.31 (-0.04)
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS(R) (prednisone) Delayed-Release Tablets
GlobeNewswire - Thu Aug 18, 6:00AM CDT
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has granted a Notice of Allowance for U.S. patent application number 14/563,000 (U.S. publication number 2015-0141388), entitled "Delayed-Release Glucocorticoid Treatment of Rheumatoid Disease" that covers Horizon's U.S. approved medicine RAYOS (prednisone) delayed-release tablets.
VEC: 26.39 (-0.52), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals™ Announces 2016 Second Quarter Results
PR Newswire - Wed Aug 10, 4:00PM CDT
Q2 net income increases to $2.5 million or $0.22 basic earnings per share - - Positive cash from operating activities of $2.1 million in the quarter -
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals(TM) Announces 2016 Second Quarter Results
CNW Group - Wed Aug 10, 4:00PM CDT
- Q2 net income increases to $2.5 million or $0.22 basic earnings per share -- Positive cash from operating activities of $2.1 million in the quarter -
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
5 Low Price-to-Book Stocks That Can Prove Valuable
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:13AM CDT
The price-to-book ratio (P/B ratio), though underrated, is also an easy-to-use valuation tool for identifying low-priced stocks with high-growth prospects.
IPXL: 24.03 (+0.09), KEP: 25.87 (+0.11), NTT: 45.31 (+0.83), HZNP: 17.84 (-0.78), DF: 17.25 (+0.20)
Horizon (HZNP) Earnings Up Y/Y, Keeps '16 View, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 1:03PM CDT
Horizon Pharma (HZNP) reported an increase of 51.4% in second-quarter 2016 earnings of 56 cents per share under the new methodology.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), HZNP: 17.84 (-0.78), CORT: 5.31 (-0.04)
Mattress Firm, Sotheby's, Horizon Pharma rise
By The Associated Press - AP - Mon Aug 08, 3:46PM CDT
Stocks that moved substantially or traded heavily on Monday:
NFLX: 97.38 (unch), AGN: 235.96 (-1.80), ON: 11.03 (+0.04), FRED: 11.05 (-0.10), HZNP: 17.84 (-0.78), BMY: 56.35 (-0.41), MFRM: 63.98 (+0.06)
Horizon (HZNP) Beats on Q2 Earnings and Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:35AM CDT
Horizon (HZNP) second-quarter 2016 results were better-than-expected with the company beating on both top- and bottom-line estimates.
HZNP: 17.84 (-0.78)
Horizon Pharma plc Announces Second-Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 08, 6:00AM CDT
-- Second-Quarter 2016 Record Net Sales of $257.4 Million, Up 49 Percent --
HZNP: 17.84 (-0.78)
5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 235.96 (-1.80), ENDP: 19.82 (-0.41), JNJ: 119.32 (+0.24), RARE: 65.13 (-1.15), KITE: 58.76 (-0.11), HZNP: 17.84 (-0.78), NVS: 79.38 (+1.11)
Rheumatology Nurses Society Announces "Heroes of Caring" Initiative Celebrating Nurses Caring For Patients With Rheumatologic Diseases
PR Newswire - Thu Aug 04, 10:30AM CDT
The Rheumatology Nurses Society (RNS), a non-profit professional nursing organization committed to the development and education of nurses to benefit patients living with rheumatologic diseases, today announced its "Heroes of Caring" project, an effort aimed at recognizing and celebrating the extraordinary efforts of rheumatology nurses. A collaborative initiative made possible with the support of Horizon Pharma plc, the project will capture rheumatology nurses' real-life stories.
HZNP: 17.84 (-0.78)
Can Horizon (HZNP) Surprise Earnings Estimates in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:10AM CDT
Horizon Pharma (HZNP), which is set to report second-quarter 2016 results on Aug 8, recorded a negative earnings surprise of 10.53% last quarter.
IPXL: 24.03 (+0.09), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95), IONS: 29.46 (-0.58)
H. D. Smith Recognizes 2016 Trading Partners of the Year
Marketwire Canada - Wed Aug 03, 2:04PM CDT
SPRINGFIELD, IL--(Marketwired - August 03, 2016) - H. D. Smith, the largest independent wholesaler in the U.S. and a leading pharmaceutical brand support company, today announced the winners of its annual Trading Partners of the Year awards, honoring select pharmaceutical and health products manufacturers. These organizations partner with H. D. Smith to collaborate actively to grow the industry and advance patient care. Each award category recognizes two winners, based on criteria including trade volume, trade policies and overall sales, for excellence across each key H. D. Smith product area. This year's Trading Partners of the Year are:
HZNP: 17.84 (-0.78)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 235.96 (-1.80), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
PR Newswire - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
CNW Group - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn
PR Newswire - Fri Sep 02, 6:40AM CDT
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, Stock-Callers.com presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX). Download the free research reports on these stocks today: http://stock-callers.com/registration
AGN: 235.96 (-1.80), AKRX: 26.47 (-0.21), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Nuvo Pharmaceuticals™ Inc. Appoints New Chief Financial Officer
PR Newswire - Thu Sep 01, 3:30PM CDT
Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer. Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller. She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration Degree from the Ivey Business School, University of Western Ontario. Ms. Burkett replaces Stephen Lemieux who has resigned to pursue other opportunities.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals(TM) Inc. Appoints New Chief Financial Officer
CNW Group - Thu Sep 01, 3:30PM CDT
Nuvo Pharmaceuticals Inc. (TSX: NRI), (Nuvo or the Company), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that Mary-Jane Burkett, has been appointed by its board of directors to the position of Vice President and Chief Financial Officer. Ms. Burkett joined Nuvo in 2012 and most recently was its Corporate Controller. She is a Chartered Professional Accountant and holds an Honours Bachelor of Business Administration Degree from the Ivey Business School, University of Western Ontario. Ms. Burkett replaces Stephen Lemieux who has resigned to pursue other opportunities.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Horizon (HZNP) Rayos Receives USPTO Notice of Allowance
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 9:22AM CDT
Horizon Pharma (HZNP) announced that it has received a notice of allowance from the U.S. Patent and Trademark Office with claims covering Rayos.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), HZNP: 17.84 (-0.78), CORT: 5.31 (-0.04)
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS(R) (prednisone) Delayed-Release Tablets
GlobeNewswire - Thu Aug 18, 6:00AM CDT
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has granted a Notice of Allowance for U.S. patent application number 14/563,000 (U.S. publication number 2015-0141388), entitled "Delayed-Release Glucocorticoid Treatment of Rheumatoid Disease" that covers Horizon's U.S. approved medicine RAYOS (prednisone) delayed-release tablets.
VEC: 26.39 (-0.52), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals™ Announces 2016 Second Quarter Results
PR Newswire - Wed Aug 10, 4:00PM CDT
Q2 net income increases to $2.5 million or $0.22 basic earnings per share - - Positive cash from operating activities of $2.1 million in the quarter -
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals(TM) Announces 2016 Second Quarter Results
CNW Group - Wed Aug 10, 4:00PM CDT
- Q2 net income increases to $2.5 million or $0.22 basic earnings per share -- Positive cash from operating activities of $2.1 million in the quarter -
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
5 Low Price-to-Book Stocks That Can Prove Valuable
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 7:13AM CDT
The price-to-book ratio (P/B ratio), though underrated, is also an easy-to-use valuation tool for identifying low-priced stocks with high-growth prospects.
IPXL: 24.03 (+0.09), KEP: 25.87 (+0.11), NTT: 45.31 (+0.83), HZNP: 17.84 (-0.78), DF: 17.25 (+0.20)
Horizon (HZNP) Earnings Up Y/Y, Keeps '16 View, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 1:03PM CDT
Horizon Pharma (HZNP) reported an increase of 51.4% in second-quarter 2016 earnings of 56 cents per share under the new methodology.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), HZNP: 17.84 (-0.78), CORT: 5.31 (-0.04)
Mattress Firm, Sotheby's, Horizon Pharma rise
By The Associated Press - AP - Mon Aug 08, 3:46PM CDT
Stocks that moved substantially or traded heavily on Monday:
NFLX: 97.38 (unch), AGN: 235.96 (-1.80), ON: 11.03 (+0.04), FRED: 11.05 (-0.10), HZNP: 17.84 (-0.78), BMY: 56.35 (-0.41), MFRM: 63.98 (+0.06)
Horizon (HZNP) Beats on Q2 Earnings and Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:35AM CDT
Horizon (HZNP) second-quarter 2016 results were better-than-expected with the company beating on both top- and bottom-line estimates.
HZNP: 17.84 (-0.78)
Horizon Pharma plc Announces Second-Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 08, 6:00AM CDT
-- Second-Quarter 2016 Record Net Sales of $257.4 Million, Up 49 Percent --
HZNP: 17.84 (-0.78)
5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 235.96 (-1.80), ENDP: 19.82 (-0.41), JNJ: 119.32 (+0.24), RARE: 65.13 (-1.15), KITE: 58.76 (-0.11), HZNP: 17.84 (-0.78), NVS: 79.38 (+1.11)
Rheumatology Nurses Society Announces "Heroes of Caring" Initiative Celebrating Nurses Caring For Patients With Rheumatologic Diseases
PR Newswire - Thu Aug 04, 10:30AM CDT
The Rheumatology Nurses Society (RNS), a non-profit professional nursing organization committed to the development and education of nurses to benefit patients living with rheumatologic diseases, today announced its "Heroes of Caring" project, an effort aimed at recognizing and celebrating the extraordinary efforts of rheumatology nurses. A collaborative initiative made possible with the support of Horizon Pharma plc, the project will capture rheumatology nurses' real-life stories.
HZNP: 17.84 (-0.78)
Can Horizon (HZNP) Surprise Earnings Estimates in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:10AM CDT
Horizon Pharma (HZNP), which is set to report second-quarter 2016 results on Aug 8, recorded a negative earnings surprise of 10.53% last quarter.
IPXL: 24.03 (+0.09), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95), IONS: 29.46 (-0.58)
H. D. Smith Recognizes 2016 Trading Partners of the Year
Marketwire Canada - Wed Aug 03, 2:04PM CDT
SPRINGFIELD, IL--(Marketwired - August 03, 2016) - H. D. Smith, the largest independent wholesaler in the U.S. and a leading pharmaceutical brand support company, today announced the winners of its annual Trading Partners of the Year awards, honoring select pharmaceutical and health products manufacturers. These organizations partner with H. D. Smith to collaborate actively to grow the industry and advance patient care. Each award category recognizes two winners, based on criteria including trade volume, trade policies and overall sales, for excellence across each key H. D. Smith product area. This year's Trading Partners of the Year are:
HZNP: 17.84 (-0.78)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 235.96 (-1.80), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
PR Newswire - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
CNW Group - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78)
(0)
(0)Scroll down for more posts ▼